Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ARID1A mutation
i
Other names:
ARID1A, AT-Rich Interaction Domain 1A, SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator Of Chromatin Subfamily F Member 1, AT-Rich Interactive Domain-Containing Protein 1A, AT Rich Interactive Domain 1A (SWI-Like), ARID Domain-Containing Protein 1A, SWI/SNF Complex Protein P270, BRG1-Associated Factor 250a, SWI-Like Protein, Osa Homolog 1, SMARCF1, C1orf4, BAF250, HOSA1, OSA1, AT Rich Interactive Domain 1A (SWI- Like), Chromatin Remodeling Factor P250, BRG1-Associated Factor 250, OS
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
8289
Related biomarkers:
Mutation
CNA
Others
‹
ARID1A mutation + MSI-H (3)
ARID1A mutation + TMB-H (1)
ARID1A underexpression + EGFR mutation (1)
KDR amplification + FLT4 amplification + MCL1 amplification + TP53 R213 + TP53 H179Y + ARID1A Q2128 (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
TMB-L + ARID1A deletion + CDKN2A deletion + CDKN2B deletion + MTAP deletion + PIK3R1 N564D + NBN P81fs*23 (1)
ARID1A mutation + PD-L1 expression (0)
ARID1A mutation + MSI-H (3)
ARID1A mutation + TMB-H (1)
ARID1A underexpression + EGFR mutation (1)
KDR amplification + FLT4 amplification + MCL1 amplification + TP53 R213 + TP53 H179Y + ARID1A Q2128 (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
TMB-L + ARID1A deletion + CDKN2A deletion + CDKN2B deletion + MTAP deletion + PIK3R1 N564D + NBN P81fs*23 (1)
ARID1A mutation + PD-L1 expression (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
ARID1A mutation
Non Small Cell Lung Cancer
ARID1A mutation
Non Small Cell Lung Cancer
durvalumab + tremelimumab-actl
Sensitive: B - Late Trials
durvalumab + tremelimumab-actl
Sensitive
:
B
durvalumab + tremelimumab-actl
Sensitive: B - Late Trials
durvalumab + tremelimumab-actl
Sensitive
:
B
ARID1A mutation
Non Small Cell Lung Cancer
ARID1A mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
ARID1A mutation
Renal Cell Carcinoma
ARID1A mutation
Renal Cell Carcinoma
sunitinib
Sensitive: B - Late Trials
sunitinib
Sensitive
:
B
sunitinib
Sensitive: B - Late Trials
sunitinib
Sensitive
:
B
ARID1A mutation
Ovarian Cancer
ARID1A mutation
Ovarian Cancer
NXP900
Sensitive: B - Late Trials
NXP900
Sensitive
:
B
NXP900
Sensitive: B - Late Trials
NXP900
Sensitive
:
B
ARID1A mutation
Ovarian Cancer
ARID1A mutation
Ovarian Cancer
NXP800
Sensitive: B - Late Trials
NXP800
Sensitive
:
B
NXP800
Sensitive: B - Late Trials
NXP800
Sensitive
:
B
ARID1A mutation
Endometrial Cancer
ARID1A mutation
Endometrial Cancer
DZR123
Sensitive: B - Late Trials
DZR123
Sensitive
:
B
DZR123
Sensitive: B - Late Trials
DZR123
Sensitive
:
B
ARID1A mutation
Ovarian Cancer
ARID1A mutation
Ovarian Cancer
DZR123
Sensitive: C2 – Inclusion Criteria
DZR123
Sensitive
:
C2
DZR123
Sensitive: C2 – Inclusion Criteria
DZR123
Sensitive
:
C2
ARID1A mutation
Hepatocellular Cancer
ARID1A mutation
Hepatocellular Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Cholangiocarcinoma
ARID1A mutation
Cholangiocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Gastric Cancer
ARID1A mutation
Gastric Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Esophageal Adenocarcinoma
ARID1A mutation
Esophageal Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ARID1A mutation
Colorectal Cancer
ARID1A mutation
Colorectal Cancer
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.